For how we live.
In PANKU-Breast01, 383 people in China with pre-treated HR-positive, HER2-negative breast cancer were randomised to izalontamab brengitecan or chemotherapy. Median progression-free survival was 8.2 versus 4.0 months.
Five-year follow-up of a Chinese randomised trial shows paclitaxel–cisplatin–capecitabine before chemoradiotherapy lifted failure-free survival from 63% to 78% in high-risk disease — at the cost of more toxicity.
In a Chinese phase 2–3 trial, neoadjuvant chemotherapy, lenvatinib and a PD-1 antibody before liver surgery lifted median event-free survival to 18.0 months from 8.7. The survival signal was not yet conclusive.